<DOC>
	<DOCNO>NCT00002437</DOCNO>
	<brief_summary>To determine whether cidofovir ( HPMPC ) therapy administer intravenous infusion extend time progression peripheral cytomegalovirus ( CMV ) retinitis AIDS patient . To evaluate safety tolerance HPMPC therapy administer intravenous infusion AIDS patient CMV retinitis immediately sight-threatening . To evaluate virologic effect intravenous HPMPC therapy CMV shed urine , blood , and/or semen . To evaluate impact HPMPC therapy visual acuity .</brief_summary>
	<brief_title>The Safety Effectiveness Cidofovir Treatment Cytomegalovirus ( CMV ) Eyes Patients With AIDS</brief_title>
	<detailed_description>Patients randomize one two treatment arm . Group A receive HPMPC IV infusion weekly 2 consecutive week ( induction ) every week ( maintenance ) oral probenecid IV hydration . Group B receive treatment time retinitis progression ( deferred treatment ) , time receive regimen Group A , provide retinitis progression immediately sight-threatening .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Probenecid</mesh_term>
	<mesh_term>Cidofovir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral agent . Oral trimethoprim/sulfamethoxazole . Aerosolized pentamidine . Dapsone . Fluconazole . Rifabutin . Filgrastim ( GCSF ) . p24 vaccine . Patients must : Diagnosis AIDS CDC criterion . Diagnosis peripheral ( immediately sightthreatening ) CMV retinitis . Visual acuity affect eye &gt; = three line ETDRS ( Early Treatment Diabetic Retinopathy Study ) chart 1 distance . Life expectancy least 3 month . Consent parent guardian patient le 18 year age . Prior Medication : Allowed : Acyclovir . Prior ganciclovir , foscarnet , CMV hyperimmune immunoglobulin give solely prophylaxis . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Media opacity precludes visualization fundus eye . Retinal detachment . Clinically significant cardiac disease , include symptom ischemia , congestive heart failure , arrhythmia . Active medical problem consider sufficient hinder study compliance . Known clinically significant allergy probenecid . Concurrent Medication : Excluded : Acyclovir ( may reinstituted follow development herpetic lesion ) . Ganciclovir . Foscarnet . Amphotericin B. Diuretics . Aminoglycoside antibiotic . CMV hyperimmune immunoglobulin . Intravenous pentamidine . Other nephrotoxic agent . Other investigational drug potential nephrotoxicity . Prior Medication : Excluded : Prior ganciclovir , foscarnet , CMV hyperimmune immunoglobulin therapy CMV disease ( although permit previously receive solely prophylaxis ) . Excluded within 1 week prior study entry : Amphotericin B. Vidarabine . Other nephrotoxic agent . Aminoglycoside antibiotic . Intravenous pentamidine . Drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 1994</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>Probenecid</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>cidofovir</keyword>
</DOC>